Clinical Trial Detail

NCT ID NCT02315625
Title Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

gastrointestinal neuroendocrine tumor

neuroendocrine tumor

islet cell tumor

pancreatic endocrine carcinoma

Therapies

Everolimus

Sunitinib

Age Groups: senior adult

Additional content available in CKB BOOST